A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

NCT06469281 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions

OTHER: 27T51
DRUG: Cemiplimab
DRUG: Bevacizumab

Sponsor

Regeneron Pharmaceuticals